* patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window * patients who have had one or more positive more than 5 days prior to enrollment but within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to enrollment and then a second positive test the day referred for enrollment, that patient would be excluded. if a patient had a positive test 5 months ago, and then another positive test the day he/she was referred for enrollment, that patient would be eligible) * unable to take oral medication * male patients with female partners of reproductive potential who are unable to maintain effective contraception during the recommended time period (during treatment and for 130 days after the final dose) * symptoms requiring hospitalization or immediate referral to hospital * taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry * known hypersensitivity to bicalutamide, or camostat, or its components. * on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) * self-reported past medical history of chronic liver disease or cirrhosis * self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction \< 40% * taking any other investigational treatment for covid-19 or covid-19 prophylaxis (covid-19 vaccines and treatments allowed under fda emergency use authorization are allowed.) women and people from all ethnic and race groups are eligible for this study.

* patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window * patients who have had one or more positive more than 5 days prior to enrollment but within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to enrollment and then a second positive test the day referred for enrollment, that patient would be excluded. if a patient had a positive test 5 months ago, and then another positive test the day he/she was referred for enrollment, that patient would be eligible) * unable to take oral medication * male patients with female partners of reproductive potential who are unable to maintain effective contraception during the recommended time period (during treatment and for 130 days after the final dose) * symptoms requiring hospitalization or immediate referral to hospital * taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry * known hypersensitivity to bicalutamide, or camostat, or its components. * on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) * self-reported past medical history of chronic liver disease or cirrhosis * self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction \< 40% * taking any other investigational treatment for covid-19 or covid-19 prophylaxis (covid-19 vaccines and treatments allowed under fda emergency use authorization are allowed.) women and people from all ethnic and race groups are eligible for this study.

- patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window - patients who have had one or more positive more than 5 days prior to enrollment but within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to enrollment and then a second positive test the day referred for enrollment, that patient would be excluded. if a patient had a positive test 5 months ago, and then another positive test the day he/she was referred for enrollment, that patient would be eligible) - unable to take oral medication - male patients with female partners of reproductive potential who are unable to maintain effective contraception during the recommended time period (during treatment and for 130 days after the final dose) - symptoms requiring hospitalization or immediate referral to hospital - taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry - known hypersensitivity to bicalutamide, or camostat, or its components. - on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) - self-reported past medical history of chronic liver disease or cirrhosis - self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction < 40% - taking any other investigational treatment for covid-19 or covid-19 prophylaxis (covid-19 vaccines and treatments allowed under fda emergency use authorization are allowed.) women and people from all ethnic and race groups are eligible for this study.

- patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window - patients who have had one or more positive more than 5 days prior to enrollment but within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to enrollment and then a second positive test the day referred for enrollment, that patient would be excluded. if a patient had a positive test 5 months ago, and then another positive test the day he/she was referred for enrollment, that patient would be eligible) - unable to take oral medication - male patients with female partners of reproductive potential who are unable to maintain effective contraception during the recommended time period (during treatment and for 130 days after the final dose) - symptoms requiring hospitalization or immediate referral to hospital - taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry - known hypersensitivity to bicalutamide, or camostat, or its components. - on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) - self-reported past medical history of chronic liver disease or cirrhosis - self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction < 40% - taking any other investigational treatment for covid-19 or covid-19 prophylaxis (covid-19 vaccines and treatments allowed under fda emergency use authorization are allowed.) women and people from all ethnic and race groups are eligible for this study.

- patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window - unable to take oral medication - self-reported pregnancy or active and unwilling to stop breastfeeding - symptoms requiring hospitalization or immediate referral to hospital - taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry - known hypersensitivity to bicalutamide, or camostat, or its components. - on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) - self-reported past medical history of cirrhosis - self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction < 40% - taking any other investigational treatment for covid-19 or covid-19 prophylaxis

- patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window - unable to take oral medication - self-reported pregnancy or active and unwilling to stop breastfeeding - symptoms requiring hospitalization or immediate referral to hospital - taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry - known hypersensitivity to bicalutamide, or camostat, or its components. - on coumadin anticoagulation (because of drug-drug interaction with bicalutamide) - self-reported past medical history of cirrhosis - self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction < 40% - taking any other investigational treatment for covid-19 or covid-19 prophylaxis